Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > ARIA-E
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(106)
•••
Comment by G1945Von Jan 09, 2025 2:45pm
61 Views
Post# 36396559

RE:RE:RE:RE:RE:RE:ARIA-E

RE:RE:RE:RE:RE:RE:ARIA-E
BottomBroker wrote: From another slide further down in the presentation...

ProMIS platform enabled generation of PMN310 which does not bind plaque or monomers, only oligomers
Attempts by others to selectively target oligomers have failed. Most drugs are not able to distinguish the different forms of Aβ and therefore bind all three or at least two forms of Aβ
Drugs that bind several forms of Aβ limit the amount of drug available to bind the key toxic form (oligomers)
Drugs that bind plaque are associated with increased serious side effects – brain swelling and microhemorrhages (ARIA-E and ARIA-H)

PMN310 doesn't bind plaque. If it did, it would cause ARIA. So, I guess they're not testing for it because there is no need to. Let's hope they're right. 


Yes. BB, I fully agree with your explanation.

The binding of AB plaque is more commonly associated with causing ARIA-E. Since the trial involves healthy volunteers, the likelihood of developing ARIA-E might be lower compared to patients with the disease. 


G1945V

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities